ICU Medical (ICUI)

• Market cap: $3.84B
• 1 day: 2.36%
• 5 days: -2.38%
• 1 month: -6.43%
• 3 months: -11.27%
• 6 months: 30.09%
• Year to date: 54.38%
• 1 year: 61.32%
• 5 years: -15.20%
• 10 years: 87.74%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Employees: 14,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

112% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 26

100% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 4 (+2) [Q3]

53% more capital invested

Capital invested by funds: $2.88B [Q2] → $4.41B (+$1.52B) [Q3]

36% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 77

11% more funds holding

Funds holding: 255 [Q2] → 284 (+29) [Q3]

0.2% less ownership

Funds ownership: 99.59% [Q2] → 99.39% (-0.2%) [Q3]

2% less call options, than puts

Call options by funds: $9.73M | Put options by funds: $9.97M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $200 28% upside
• Avg. target: $205 30% upside
• High target: $209 33% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Jefferies Michael Toomey 0% 1-year accuracy 0 / 1 met price target	28% upside $200	Buy Upgraded	11 Dec 2024
Keybanc Brett Fishbin 65% 1-year accuracy 13 / 20 met price target	33% upside $209	Overweight Maintained	13 Nov 2024